Institute of Biological Chemistry
The Institute of Biological Chemistry is part of the Faculty of Chemistry at the University of Vienna with strong links to the Centre for Physiology and Pharmacology of the Medical University of Vienna, the Max F. Perutz Laboratories with their focus on Molecular and Structural Biology, and the Institute of Food Chemistry and Toxicology. It is supported by state-of-the-art core facilities, including MS, NMR, X-ray, nanostructures, and multimodal imaging. Together, this forms an outstanding environment for research at the interface of synthetic chemistry, molecular biology, pharmacology and medicine.
The Faculty of Chemistry is one of the largest postgraduate training centres in Austria and its highly-intellectual and well-equipped environment is complemented by strong career development programs of the University of Vienna. Its young and diverse faculty offers a vibrant and innovative environment for young researchers from around the world starting at the level of PhD students and postdocs towards junior group leaders that want to establish their own research line.
University of Vienna
Open to new ideas. Since 1365. The University of Vienna (15 faculties, 4 centres, >150 fields of study, ~9,500 members of staff, >90,000 students) is a research university with high international visibility and a wide range of degree programs. The University of Vienna is committed to fundamental and applied research, research-led teaching, career development for young researchers and to a dialogue with economy and society. Appointments of high-quality researchers is an important strategy of the University of Vienna to contribute to the education of future generations and to the society’s ability to innovate.
The Institute for Molecular Biology is one of Australia’s premier research institutes and is structured into three divisions: Chemistry and Structural Biology, Genomics of Development and Disease, and Molecular Cell Biology. It comprises >450 staff in more than 30 research groups, which are supported by state-of-the-art instrumentation and core facilities, including a high-resolution mass spectrometry facility, a next-generation sequencing facility, a X-ray crystallization facility, a NMR facility (900 MHz, 600 MHz, 500 MHz), a high-throughput-screening platform, and an advanced imaging (fluorescent spectroscopy, confocal microscopy) facility.
The University of Queensland is ranked in the top 1% of world universities and is one of Australia’s top three universities with more specialised fields of research well-above world standard than any other Australian university, as confirmed by the Federal Government’s 2018 Excellence in Research for Australia exercise. UQ continues to be Australia's highest-ranking institution on the Nature Index with a global reputation as a top-tier research organisation. It is a highly intellectual environment that attracts a continuous flux of research leaders from around the world. UQ’s research strengths reflect this broad scope of activity, with 30 recognised research strengths, including Molecular Bioscience; Drug Design; Nanotechnology and Bioengineering; Immunology and Infectious Diseases; Cancer Studies; Neurosciences; Information Systems and Computational Science; and Genetics and Genomics. UQ fosters fundamental, curiosity-driven work that builds the stock of knowledge and leads to new research questions to applied research and innovation with direct applications for industry and the public.
UniQuest Pty Ltd is the main commercialisation company of UQ and widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. Established in 1984, UniQuest has built, commercialised and managed an extensive intellectual property and asset portfolio, including more than 1,500 patents and 70 companies resulting from university-based discoveries and expertise. Since 2000, UniQuest and its start-ups have raised half a billion dollars to take UQ technologies to market. Net sales of products licensed by UniQuest total more than $13 billion for the period 2007–2015. UniQuest was responsible for the commercialisation of the HPV vaccine Gardasil®, the Triple P Positive Parenting Program, the image correction technology used in two-thirds of the world's MRI machines, and Spinifex Pty Ltd – a pain-focused biopharmaceutical company acquired recently by Novartis in one of Australia's largest ever biotech deals.